1 |
Han MK, Agusti A, Calverley PM. et a1. Chronic obstructive pulmonary Disease phenotypes:the future of COPD [J]. Am J Respir Crit Care Med, 2010, 182(5): 598-604.
|
2 |
Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort [J]. Lancet Respir Med, 2017, 5: 619-626.
|
3 |
Liang L, Cai Y, Barratt B, et al. Associations between daily air quality and hospitalisations for acute exacerbation of chronic obstructive pulmonary disease in Beijing, 2013-17: an ecological analysis [J]. Lancet Planet Health, 2019, 3: e270-9.
|
4 |
Butler CC, Gillespie D, White P, et al. C-Reactive protein testing to guide antibiotic prescribing for COPD exacerbations [J]. N Engl J Med, 2019, 381: 111-120.
|
5 |
Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: immunological, epidemiological, and clinical aspects [J]. Front Med, 2021, 7: 627278.
|
6 |
Rossi GA. COPD patients or "healthy smokers": is IL-8 synthesis and release the borderline? [J]. Resp, 2003, 70: 457-459.
|
7 |
Montuschi P, Macagno F, Parente P, et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD [J]. Thorax, 2005, 60(10): 827-833.
|
8 |
Zhang J, Yao W, You X, et al. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China [J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1195-1207.
|
9 |
Li F, Sun Z, Li H, et al. Factors associated with hospitalisation costs in patients with chronic obstructive pulmonary disease [J]. Int J Tuberc Lung Dis, 2018, 22: 458-463.
|
10 |
Ni W, Bao J, Yang D, et al. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis [J]. Infect Dis (Lond), 2019, 51: 639-650.
|
11 |
Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT [J]. Health Technol Assess, 2020, 24: 1-108.
|
12 |
晏斌林, 顾为丽, 杜娟, 等. COPD患者呼出气冷凝液IL-17、IL-10、8-iso-PG 的测定及临床意义 [J]. 中国呼吸与危重监护杂志, 2017, (2): 142-146.
|
13 |
王新航, 翁恒, 李红艳, 等. COPD不同分期全身炎症与呼出气冷凝液炎症指标的变化及相互关系 [J]. 中外医疗, 2018, (36): 19-21.
|
14 |
Jónsdóttir B, Jaworowski Å, San Miguel C, et al. IL-8 predicts early mortality in patients with acute hypercapnic respiratory failure treated with noninvasive positive pressure ventilation [J]. BMC Pulm Med, 2017, 17(1): 35.
|
15 |
Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease [J]. Tanaffos, 2018, 17(1): 13-21.
|
16 |
Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD [J]. Thorax, 2003, 58: 294-298.
|
17 |
麻佑锋, 郑有光, 韩利红, 等. 哮喘-慢阻肺重叠患者EBC 中 8-isoPG、LTB4 及 PCT 检测的意义 [J]. 临床肺科杂志, 2018, 10(23): 1812-1814.
|
18 |
李小莉, 黄平, 杜秀芳. COPD治疗期间呼出气冷凝液中8-异前列腺素、IL-6、IL-10的变化及与气道炎症的相关性研究 [J]. 中国呼吸与危重监护杂志, 2014, 13(5): 445-448.
|
19 |
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers [J]. Am J Respir Crit Care Med, 2011, 184(6): 662-671.
|
20 |
Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort [J]. Lancet Respir Med, 2017, 5(12): 956-967.
|
21 |
Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD [J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1819-1824.
|
22 |
Criner GJ, Celli BR, Singh D, et al. Predicting response to Benralizumab in chronic obstructive pulmonary disease :Analyses of GALATHEA and TERRANOVA studies [J]. The Lancet Respiratory Medicine, 2020, 8(2): 158-170.
|
23 |
Yun JH, Lamb A, Chase R, et al.Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease [J]. J Allergy Clin Immunol, 2018, 141(6): 2037-2047.
|
24 |
曾强林, 王晓明, 李珊娜, 等. COPD急性加重患者血嗜酸粒细胞增高的发生情况及临床特征 [J]. 中华医学杂志, 2017, 97(40): 3166-3170.
|
25 |
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial [J]. Lancet Respir Med, 2016, 4(5): 390-398.
|
26 |
Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD [J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1819-1824.
|
27 |
Yang H, Xiang P, Zhang E, et al. Predictors of exacerbation frequency in chronic obstructive pulmonary disease [J]. Eur J Med Res, 2014, 19(1): 18.
|